Key result
PPAR activators used for metabolic complications have both beneficial and detrimental effects on myocardial function, which is critical given the expanding prevalence of heart failure.
This review highlights the complex dual nature of PPAR activators, which offer metabolic benefits for conditions like diabetes and hyperlipidemia but may also pose risks of adverse effects on cardiac function.
PPARs may represent therapeutic targets in HF; leaves open clinical utility pending prospective trials.
Over 5 million people in the United States suffer from the complications of heart failure (HF), which is a rapidly expanding health complication. Disorders that contribute to HF include ischemic cardiac disease, cardiomyopathies, and hypertension. Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor family. There are three PPAR isoforms: PPARα, PPARγ, and PPARδ. They can be activated by endogenous ligands, such as fatty acids, as well as by pharmacologic agents. Activators of PPARs are used for treating several metabolic complications, such as diabetes and hyperlipidemia that are directly or indirectly associated with HF. However, some of these drugs have adverse effects that compromise cardiac function. This review article aims to summarize the current basic and clinical research findings of the beneficial or detrimental effects of PPAR biology on myocardial function.
No takes yet. Share an insight, caveat, or question.
Pol et al. (2015) conducted a review in Heart failure. PPAR activators was evaluated. PPAR activators used for metabolic complications have both beneficial and detrimental effects on myocardial function, which is critical given the expanding prevalence of heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: